EPISODE · Sep 26, 2025 · 8 MIN
#042 $NVO’s 25 Percent Problem
from SueWallSt · host SueWallSt
Novo Nordisk $NVO promised blockbuster weight loss from its new drug CagriSema—touting 25% results. But when final trial data landed at 22.7%, investors were stunned. In this episode of Bulls & Betrayal, Anna and Nate dig into the class action lawsuit accusing Novo of misleading shareholders about trial design and results. Perfect for biotech investors, legal watchers, and pharma skeptics, this episode exposes the risks behind drug hype. Add our WhatsApp Channel. Visit ZLK.com for more info. We’re not lawyers or accountants, so don’t take this as legal or financial advice.
What this episode covers
Novo Nordisk $NVO promised blockbuster weight loss from its new drug CagriSema—touting 25% results. But when final trial data landed at 22.7%, investors were stunned. In this episode of Bulls & Betrayal, Anna and Nate dig into the class action lawsuit accusing Novo of misleading shareholders about trial design and results. Perfect for biotech investors, legal watchers, and pharma skeptics, this episode exposes the risks behind drug hype. Add our WhatsApp Channel. Visit ZLK.com for more info. We’re not lawyers or accountants, so don’t take this as legal or financial advice.
NOW PLAYING
#042 $NVO’s 25 Percent Problem
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.